Skip to content
Disclosery

Consonance Capital Management LP

Follow

13F filer, CIK 1544773, New York, NY

Consonance Capital Management LP reported $58,946,000 across 8 holdings for the quarter ended 2022-03-31, in a 13F-HR filed 2022-05-16.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001085146-22-002165

Period
2022-03-31
Reported value
$58.9M
Holdings
8
Top 10 weight
100%
New
0
Sold out
7

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
GMEDreduced-266,230-$19.6M
TNDMreduced-153,337-$17.8M
UTHRreduced-35,275-$6.33M
JIYA ACQUISITION CORPexited-300,000-$2.93M
RESEARCH ALLIANCE CORP IIexited-300,000-$2.93M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2022

Share positions as resolved from 13F-HR 0001085146-22-002165, largest first. % of portfolio is the value over $58,946,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
TNDMTANDEM DIABETES CARE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: 979,226 shares; 2021Q3: 487,327 shares; 2021Q4: 300,664 shares; 2022Q1: 147,327 shares 147,327$17.1M29.07%-153,337Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: 222,222 shares; 2021Q2: 222,222 shares; 2021Q3: 178,787 shares; 2021Q4: 758,253 shares; 2022Q1: 654,108 shares 654,108$12.4M21.08%-104,145Timeline
Surrozen, Inc.Surrozen, Inc.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: 1,000,000 shares; 2021Q4: 3,497,500 shares; 2022Q1: 3,497,500 shares 3,497,500$10.5M17.86%0
GMEDGLOBUS MED INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 908,953 shares; 2021Q1: 578,371 shares; 2021Q2: 1,084,979 shares; 2021Q3: 589,100 shares; 2021Q4: 373,254 shares; 2022Q1: 107,024 shares 107,024$7.9M13.4%-266,230Timeline
CMPXCOMPASS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: not reported; 2021Q4: 3,500,000 shares; 2022Q1: 3,500,000 shares 3,500,000$4.74M8.05%0Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 528,964 shares; 2021Q1: 558,162 shares; 2021Q2: 159,087 shares; 2021Q3: 157,838 shares; 2021Q4: 59,838 shares; 2022Q1: 24,563 shares 24,563$4.41M7.48%-35,275Timeline
MOONLAKE IMMUNOTHERAPEUTICSMOONLAKE IMMUNOTHERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 150,000 shares; 2021Q1: 150,000 shares; 2021Q2: 150,000 shares; 2021Q3: 150,000 shares; 2021Q4: 150,000 shares; 2022Q1: 137,000 shares 137,000$1.52M2.58%-13,000
SRZNWSURROZEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: not reported; 2021Q1: not reported; 2021Q2: not reported; 2021Q3: 333,333 shares; 2021Q4: 1,165,832 shares; 2022Q1: 1,165,832 shares 1,165,832$291K0.49%0Timeline

Sold out in Q1 2022

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
RESEARCH ALLIANCE CORP IIRESEARCH ALLIANCE CORP II300,000$2.93Mshares
JIYA ACQUISITION CORPJIYA ACQUISITION CORP300,000$2.93Mshares
MEDICUS SCIENCES ACQUISITIONMEDICUS SCIENCES ACQUISITION300,000$2.92Mshares
ARYA SCIENCES ACQUISITN CORPARYA SCIENCES ACQUISITN CORP300,000$2.91Mshares
PANACEA ACQUISITION CORP IIPANACEA ACQUISITION CORP II200,000$1.94Mshares
CAREMAX INCCAREMAX INC45,960$64Kshares
MEDICUS SCIENCES ACQUISITIONMEDICUS SCIENCES ACQUISITION33,331$24Kshares

How Q1 2022 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001085146-22-002165 base2022-05-16acceptance time not in the bulk data set